More Cambium Bio Ltd news
Cambium Bio LtdASX: CMB

Chinese patent granted for biomarkers for stem cell therapy

Dec 2, 2018 at 10:55 PM EST · Issued by Cambium Bio Ltd

Filed with ASX · Dec 2, 2018 at 10:55 PM EST · 2 pages · English

On 6ix: 6ix.com/news/chinese-patent-granted-for-biomarkers-for-stem-cell-therapy

Cambium Bio Ltd on 6ix

Story so far

  • Progenza patent to grant in EuropeOct 18, 2018
  • US Patent Office to allow key patent for ProgenzaJul 10, 2018
  • Japanese Patent Office to grant patent for cancer vaccineFeb 12, 2018

Earlier from Cambium Bio

  • Re-Released - Appendix 4C - QuarterlyOct 23, 2018
  • Progenza patent to grant in EuropeOct 17, 2018
  • Regeneus receives R&D tax incentive refund of $2.4mSep 5, 2018
  • Positive clinical trial results for cancer vaccineJul 30, 2018
  • US Patent Office to allow key patent for ProgenzaJul 9, 2018

Later from Cambium Bio

  • New CEO Appointed to Accelerate Global GrowthJan 22, 2019
  • Response to ASX Appendix 4C Query LetterFeb 21, 2019
  • Directors Provide $2.5M Loan to Extend Funding RunwayFeb 28, 2019
  • Positive results for Progenza in treating neuropathic painJul 23, 2019
  • Successful Private PlacementAug 1, 2019
All Cambium Bio news releases↗

Follow Cambium Bio into a list and get an email when it puts out news.

Follow Cambium Bio
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer